Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

被引:20
|
作者
Weissfeld, JL
Fagerstrom, RM
O'Brien, B
机构
[1] NCI, Div Canc Prevent, Biometry Res Grp, Bethesda, MD 20892 USA
[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[3] Westat Inc, Rockville, MD USA
来源
CONTROLLED CLINICAL TRIALS | 2000年 / 21卷 / 06期
关键词
quality control; cancer screening; procedures; data analysis;
D O I
10.1016/S0197-2456(00)00094-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Investigators for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial describe quality control procedures for the digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, and flexible sigmoidoscopy. These cancer screening tests are subjective and difficult to standardize. PLCO quality control procedures aim to measure and, where possible, reduce variation, across examiner and screening center, with respect to cancer screening test performance. Initial protocols stressed examiner qualifications, experience, and training; equipment specifications; examination procedures; and definitions for positive tests. The PLCO quality assurance subcommittee developed a final quality assurance plan, which included central approval and registration of PLCO examiners, direct observation of screening test performance during periodic site visits by the National Cancer Institute and coordinating center auditors, periodic analysis of screening test data, and procedures for independently duplicating or reviewing selected examinations. For each modality, the periodic data analyses examine the test-positive and the test-inadequate proportions and aim to identify divergent centers or examiners. Procedures for duplicating examinations specify feasible sample sizes for precise estimates of agreement between examiners, at each center, for each screening test modality, and over a 1-year period. These quality control procedures will help characterize the consistency and reliability of the PLCO cancer screening tests. Control Clin Trials 2000;21:390S-399S (C) Elsevier Science Inc. 2000.
引用
收藏
页码:390S / 399S
页数:10
相关论文
共 50 条
  • [41] Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Marcus, Pamela M.
    Ogden, Sheryl L.
    Gren, Lisa H.
    Childs, Jeffery C.
    Pretzel, Shannon M.
    Lamerato, Lois E.
    Walsh, Kayo
    Rozjabek, Heather M.
    Mabie, Jerome
    Thomas, Brett
    Riley, Tom
    PREVENTIVE MEDICINE, 2014, 67 : 82 - 88
  • [42] The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The prostate cancer screening results in context
    Berg, Christine D.
    ACTA ONCOLOGICA, 2011, 50 : 12 - 17
  • [43] Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial
    Miller, J. H.
    Kramer, B. S.
    Kreimer, A. R.
    Prorok, P. C.
    Xu, J.
    Baker, S. G.
    Fagerstrom, R.
    Berg, C. D.
    Gohagan, J. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] The Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening trial: status and promise
    Andriole, GL
    Reding, D
    Hayes, RB
    Prorok, PC
    Gohagan, JK
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) : 358 - 361
  • [45] CELL CYCLE GENETIC VARIANTS ASSOCIATED WITH AGGRESSIVE PROSTATE CANCER IN THE PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER SCREENING TRIAL
    Huynh, Melissa J.
    Penney, Kathryn L.
    Vyas, Chirag
    Kibel, Adam S.
    JOURNAL OF UROLOGY, 2019, 201 (04): : E81 - E81
  • [46] Dietary patterns predict mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort
    Tseng, Marilyn
    Graubard, Barry I.
    Ziegler, Regina
    FASEB JOURNAL, 2011, 25
  • [47] Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The first six years
    Simpson, NK
    Johnson, CC
    Ogden, SL
    Gamito, E
    Trocky, N
    McGuire, C
    Martin, J
    Barrow, S
    Lamerato, L
    Flickinger, LM
    Broski, KG
    Engelhard, D
    Hilke, C
    Bonk, J
    Gahagan, B
    Gren, LH
    Childs, J
    Lappe, K
    Fouad, M
    Thompson, J
    Sullivan, D
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 356S - 378S
  • [48] No association between vitamin K intake and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)
    Hoyt, Maggie
    Reger, Michael
    Zhang, Jianjun
    CANCER RESEARCH, 2017, 77
  • [49] Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Miller, Anthony B.
    Feld, Ronald
    Fontana, Robert
    Gohagan, John K.
    Jatoi, Ismail
    Lawrence, Walter, Jr.
    Miller, Amy
    Prorok, Philip C.
    Rajput, Ashwani
    Sherman, Morris
    Welch, Gilbert
    Wright, Patrick
    Yurgalevitch, Susan
    Albertsen, Peter
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (03) : 206 - 211
  • [50] Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Hasson, MA
    Fagerstrom, RM
    Kahane, DC
    Walsh, JH
    Myers, MH
    Caughman, C
    Wenzel, B
    Haralson, JC
    Flickinger, LM
    Turner, LM
    CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 329S - 348S